For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

TRANSLATION TO CLINIC CONCURRENT New Frontiers in CGT for Cardiovascular Diseases
Thursday, June 1, 2023 05:00 PM - 06:00 PM  
Room 242AB
TRANSLATION TO CLINIC
Concurrent
Co-Chairs
Massimiliano Gnecchi, MD, PhD, FESC, Professor, University of Pavia, & Fondazione IRCCS Policlinico San Matteo, Italy
Giulio Pompilio, MD, PhD, CARE working group of the European Society of Cardiology, Italy

Speakers
Doris Taylor, PhD, FACC, FAHA, Organamet Bio Inc.
Michael Schuster, MS, MBA, Head of Business Development and Project Management, Mesoblast, USA
Kikuo Yasui, MSc, Chief Operating Officer, Director of Board, Heartseed Inc., Japan

Session Description
First-generation cell therapies for the treatment of heart disease have not yielded significant results despite promising data from animal models. Now the results of a second generation of cell therapies appear to indicate benefits and give hope to millions of patients in need. In this session, top-notched experts will present the latest achievements and remaining hurdles of this sector.
 

Massimiliano Gnecchi MD, PhD, FESC
Professor
University of Pavia & Fondazione IRCCS Policlinico San Matteo
Chair


Giulio Pompilio MD, PhD
CARE working group of the European Society of Cardiology
Chair


Silviu Itescu MBBS, FRACP
Chief Executive Officer & Managing Director
Mesoblast Inc.
Speaker


Doris Taylor PhD, FACC, FAHA, FESC, FAIMBE
CEO
Organamet Bio
Speaker


Kikuo Yasui MSc
Chief Operating Officer, Director of Board
Heartseed Inc.
Speaker